Literature DB >> 31290583

Barretts's carcinogenesis.

Ken-Ichi Mukaisho1, Shunpei Kanai1, Ryoji Kushima2, Takahisa Nakayama1, Takanori Hattori1, Hiroyuki Sugihara1.   

Abstract

Barrett's esophagus is considered a precancerous lesion of esophageal adenocarcinoma (EAC). Long-segment Barrett's esophagus, which is generally associated with intestinal metaplasia, has a higher rate of carcinogenesis than short-segment Barrett's esophagus, which is mainly composed of cardiac-type mucosa. However, a large number of cases reportedly develop EAC from the cardiac-type mucosa which has the potential to involve intestinal phenotypes. There is no consensus regarding whether the definition of Barrett's epithelium should include intestinal metaplasia. Basic researches using rodent models have provided information regarding the origins of Barrett's epithelium. Nevertheless, it remains unclear whether differentiated gastric columnar epithelium or stratified esophageal squamous epithelium undergo transdifferentiation into the intestinal-type columnar epithelium, transcommittment into the columnar epithelium, or whether the other pathways exist. Reflux of duodenal fluid including bile acids into the stomach may occur when an individual lies down after eating, which could cause the digestive juices to collect in the fornix of the stomach. N-nitroso-bile acids are produced with nitrites that are secreted from the salivary glands, and bile acids can drive expression of pro-inflammatory cytokines via EGFR or the NF-κB pathway. These steps may contribute significantly to carcinogenesis.
© 2019 The Authors. Pathology International published by the Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Barret's esophagus; bile acid, gastroesophageal reflux, metaplasia

Mesh:

Year:  2019        PMID: 31290583      PMCID: PMC6851828          DOI: 10.1111/pin.12804

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


EPIDEMIOLOGY OF ESOPHAGEAL CANCER

Histological studies have revealed that the main epithelial malignant tumors of the esophagus are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), which have different risk factors.1 The primary risk factor for EAC is gastroesophageal reflux disease (GERD).2, 3, 4 GERD is a major cause of reflux esophagitis, which occurs when gastric acid, bile acids and other harmful substances in gastric juice flow backward into the esophagus,5 which is generally covered with stratified squamous epithelium. Most esophageal cancers in Asian countries, including Japan, involve ESCC.6, 7 In contrast, Western countries have recently seen a sharp increase in the prevalences of EAC and esophagogastric junction cancer.8 In the US, EAC accounts for approximately 60% of all esophageal cancers, and ESCC had historically been predominant, although EAC appears to have overtaken ESCC in approximately 1995.7, 9, 10 This change may be related to the sharp increase in the number of obese individuals with a high‐fat diet and the resulting increase in the prevalence of GERD.7, 8, 11, 12 Japan has also seen an increase in the prevalence of GERD, in conjunction with increasingly Westernized dietary habits, a reduced rate of Helicobacter pylori (H. pylori) infection and an expanding elderly population.13, 14, 15, 16, 17, 18, 19, 20, 21 Thus, there are fears that the prevalence of EAC will continue to gradually increase.22

DEFINITION OF BARRETT'S ESOPHAGUS

Barrett's epithelium is metaplasia from squamous epithelium into columnar epithelium,23 with esophageal Barrett's epithelium being known as Barrett's esophagus.24 Barrett's esophagus is considered a precancerous lesion of EAC, although there is no universally accepted definition of Barrett's esophagus.25 The key factor in defining Barrett's esophagus involves the presence of goblet cells, and there is no disagreement that Barrett's esophagus involves a columnar epithelium. The American definition of Barrett's epithelium only considers intestinal metaplastic mucosa with goblet cells (Fig. 1a), which has led to the use of the phrase ‘no goblets, no Barrett's’.26, 27, 28 In Germany, the histological diagnosis of Barrett's esophagus still requires the proof of a specialized intestinal metaplastic epithelium (columnar epithelium with goblet cells).29 In contrast, the Japanese definition of Barrett's mucosa is ‘columnar epithelium continuous from the stomach with or without intestinal metaplasia’24 (Fig. 1b). The British Society of Gastroenterology also defines this condition as ‘an esophagus in which any portion of the normal distal squamous epithelial lining has been replaced by metaplastic columnar epithelium and includes a ≥ 1 cm segment length criterion’, regardless of whether goblet cells are present.30
Figure 1

Definition of Barrett's esophagus. (a) Intestinal metaplasia with goblet cells. (b) Columnar epithelium without goblet cells. The American and German definition of Barrett's epithelium only considers intestinal metaplastic mucosa with goblet cells (a). In contrast, the Japanese and British definition of Barrett's mucosa does not require goblet cells (b). However, in the British Society of Gastroenterology includes a ≥ 1 cm segment length criterion.

Definition of Barrett's esophagus. (a) Intestinal metaplasia with goblet cells. (b) Columnar epithelium without goblet cells. The American and German definition of Barrett's epithelium only considers intestinal metaplastic mucosa with goblet cells (a). In contrast, the Japanese and British definition of Barrett's mucosa does not require goblet cells (b). However, in the British Society of Gastroenterology includes a ≥ 1 cm segment length criterion.

WHERE IS THE ESOPHAGOGASTRIC JUNCTION?

In the UK, a ≥ 1‐cm segment of columnar epithelium fulfills the definition of Barrett's esophagus,30 with Barrett's epithelium being classified based on its length into short‐segment Barrett's esophagus (SSBE; a < 3‐cm segment) and long‐segment Barrett's esophagus (LSBE; a ≥ 3‐cm segment).24 Thus, the distance from the esophagogastric junction is key to defining and classifying Barrett's esophagus, although this must be based on the precise location of the esophagogastric junction. In Western countries, the esophagogastric junction is endoscopically defined as the upper margin of the gastric mucosal folds (the oral margin of the longitudinal folds of the greater curvature of the stomach), whereas in Japan the esophagogastric junction is defined as the lower end of the palisade vessels.31, 32, 33, 34, 35 The histological requirements of this definition are the presence of (i) esophageal gland ducts in the mucosal layer or proper esophageal glands in the submucosal layer within the area of columnar epithelium;36, 37 (ii) squamous islands in the columnar epithelium;38 and (iii) a double‐layer muscularis mucosae.37 Recently, palisade vessels have also been reported as a new histologic marker of esophageal origin.39

LENGTH OF BARRETT'S ESOPHAGUS AND CARCINOGENESIS

In the US, 5.6% of adults have LSBE and 10 to 15% of adults have SSBE.12, 40 In Japan, the rates are approximately 17.9% (1.2–59.0%) for SSBE and approximately 0.4% (0.2–1.4%) for LSBE,41 with SSBE also being more common in other Asian countries.42, 43, 44 Barrett's esophagus is thought to have an annual carcinogenesis rate of 0.15 to 0.65%.45, 46 Other reports have also examined the carcinogenesis risk of Barrett's esophagus, with some reports attributing similar risks to SSBE and LSBE47 and other recent reports indicating the LSBE has a greater carcinogenesis risk than SSBE.48, 49 One recent report from Japan focusing on follow‐up of patients with LSBE revealed a carcinogenesis rate of approximately 1.2% per year (3 cancers/251 cases/year; 12 cases per 1000 people),50 which is higher than the reported rates from other countries. This discrepancy may be related to the small sample size of the Japanese study, although it could also be attributed to the different diagnostic criteria for adenocarcinoma in Japan and Western countries. The Vienna classification was published by a global group of gastrointestinal pathologists to unify the diagnostic criteria for tumors of the gastrointestinal tract,51 although it is practically difficult to achieve this unification. For example, some intramucosal atypical gland‐forming lesions are diagnosed as EAC in Japan, even in cases that would be diagnosed as low‐grade or high‐grade dysplasia in Western countries. This difference is related to Western countries defining carcinoma as involving invasion, while the Japanese definition is based on nuclear and structural atypia. Therefore, in Western countries, most mucosal lesions with nuclear or structural atypia (except poorly‐differentiated adenocarcinoma or undifferentiated tumors, such as signet ring cell carcinoma) would be classified as dysplasia and not cancer.

BARRETT'S EPITHELIUM: HISTOLOGICAL TYPE AND CARCINOGENESIS

The designation Barrett's esophagus arises from Barrett's report describing ‘part of the foregut, distal to the cricopharyngeal sphincter, which is lined by squamous epithelium’.52 The report also notes that ‘He commented on earlier reports describing patients with ulcerations in a tubular organ that grossly appeared to be the esophagus but had a distal, ulcerated portion lined by columnar epithelium’.53 At the time, it was considered a form of the stomach that was congenitally present in the esophagus, which was referred to as ‘short esophagus’.52, 53 The term ‘Barrett's esophagus’ was not initially used. Various reports subsequently provided histological images of Barrett's esophagus, with Paul et al.54 presenting images from 11 cases of Barrett's esophagus in 1976, which they concluded showed three types of columnar epithelium in the lower esophagus: atrophic gastric mucosa (now ‘oxyntic mucosa’), junctional mucosa (now ‘cardiac‐type mucosa’), and specialized columnar epithelium (‘intestinal metaplasia’). This report conflicts with the current American diagnostic criteria for Barrett's epithelium, which emphasize intestinal metaplasia, while reports from the 1980s implicated intestinal metaplasia in the development of Barrett's esophagus and various epithelial cancers, although intestinal metaplasia was considered essential to the definition of Barrett's esophagus (a precancerous lesion).55, 56, 57, 58, 59, 60 As intestinal metaplasia is often seen as a histological type of LSBE, intestinal metaplasia could also be considered essential for carcinogenesis in the US. However, the concept that intestinal metaplasia is required for cancer to develop has become a sort of dogma in the US. The choice of the word “dogma” can be better understood by considering the example of gastric carcinogenesis. It is common knowledge that gastric cancer is often caused by Helicobacter pylori infection, which causes superficial gastritis to become chronic active gastritis, and chronic atrophic gastritis subsequently results in intestinal metaplasia leading to gastric cancer (especially differentiated gastric cancer).61, 62 In the US, research revealed that intestinal metaplasia was commonly found in the background mucosa of gastric cancer, before the discovery of H. pylori, which led to the belief that intestinal metaplasia was a precancerous lesion leading to gastric cancer.63, 64

IS IT TRUE THAT ‘ONLY INTESTINAL METAPLASIA RESULTS IN CANCER’?

The process of esophageal and gastric carcinogenesis raises questions regarding the hypothesis that ‘only intestinal metaplasia results in cancer’. For example, Hattori's 1985 study investigated mucous granules from gastric cancer cells occurring in hyperplastic polyps without any intestinal metaplasia and revealed that gastric cancer developed from intrinsic gastric glands.65 We also recently reported that gastric cancer is also observed developing with hyperplastic polyps in the background and proved the genomic change in this intramucosal lesion.66 Subsequent research has aimed to study the mucous phenotypes of gastric cancer and its background mucosa.67, 68, 69, 70, 71 In this context, gastric cancer reportedly occurs from intrinsic gastric glands that have atrophied with sufficiently intense inflammation to cause intestinal metaplasia.72 It means that intestinal metaplasia is not always a ‘precancerous’ lesion but a ‘paracancerous’ lesion. In our recent report, we found that early intramucosal gastric cancer lesions possessed gastric mucous phenotypes and that there is a proliferative zone with a polarity of differentiation in mucous phenotypes that is similar to the intrinsic gastric glands.73 Thus, it does not appear that intestinal metaplasia is a major oncogenic pathway for gastric cancer. This gland‐forming differentiated adenocarcinoma with gastric mucous phenotype is finally gaining global recognition, and even the widely accepted 2011 WHO system classifies gastric phenotype neoplasia.74

SOME EACs DEVELOP FROM GASTRIC‐TYPE MUCOSA

An analysis of EACs reported in 2009, using German cases, revealed that small EACs do not exclusively develop from intestinal metaplasia, and can develop from gastric cardiac‐type mucosa.75 A report from the UK has also stated that intestinal metaplasia is not a universally‐present component of oncogenesis.76 Columnar metaplasia without goblet cells can involve abnormal DNA. Results from the other studies of EAC also revealed that these tumors were often gastric phenotype.77, 78 These results confirm that EAC development is not restricted to the intestinal metaplasia. Columnar metaplasia without goblet cells also reportedly has the potential to involve intestinal phenotypes.79, 80, 81, 82 In German cases, approximately 60% of Barrett's mucosa on the background of EAC in the lower esophagus was cardiac‐type mucosa without goblet cells, although the glands often had intestinal phenotypes (versus pure gastric phenotypes) with the expression of intestinal phenotypes claudin 3 and claudin 4.77 Epidemiological data indicate that LSBE, which is often associated with intestinal metaplasia, has a higher carcinogenesis rate than SSBE, and that cases with a background of intestinal metaplasia often have intense inflammation and severe reflux esophagitis. Thus, Barrett's epithelium involving intestinal metaplasia is likely to involve more intense reflux‐based irritation, and it might be understood that Barrett's epithelium with intestinal metaplasia involves a higher risk of carcinogenesis than if intestinal metaplasia was absent.

RELATIONSHIP BETWEEN BARRETT'S EPITHELIUM AND GASTRODUODENAL REFLUX

A previous report in 1979 indicated that Barrett's esophagus developed after total gastrectomy in humans, which suggested that gastric acid reflux was not necessary for Barrett's esophagus to occur.83 It is now widely accepted that reflux of both gastric acid and bile acids must be involved for Barrett's epithelium to occur.84 To evaluate the histogenesis of Barrett's epithelium, many researchers, including our group, have used rat models of surgically induced gastroduodenal reflux that causes reflux of duodenal fluid, including bile acids, with or without gastric juice, into the esophagus85, 86, 87, 88 (Fig. 2). These models have revealed that, even in the absence of carcinogenic agents, Barrett's epithelium with intestinal metaplasia developed 10 to 20 weeks after surgery, and dysplasia and EAC could be observed after approximately 40 weeks85, 86, 87, 88 (Fig. 3). Thus, reflux of duodenal fluid, including bile acids, is essential for Barrett's epithelium with goblet cells to occur. In contrast, reflux of gastric juice without duodenal fluid only induces light esophagitis and does not appear to produce Barrett's esophagus with intestinal metaplasia.77 In vitro experiments have indicated that exposure to bile acids can induce the expression of CDX1 and CDX2, which are transcription factors that are involved in the production/maintenance of the intestinal epithelium.89, 90, 91 Therefore, bile acid reflux has been implicated as being involved in the occurrence of Barrett's esophagus with intestinal metaplasia.
Figure 2

Various rat reflux models of Barrett's esophagus leading to adenocarcinoma. F, forestomach; G, glandular stomach; T, treitz ligament. (a) Esophago‐jejunostomy after total gastrectomy.86, 87 (b) Esophago‐jejunostomy without gastrectomy.87, 88 (c) The esophagogastric junction was side‐to‐side anastomosed to a loop of jejunum.93

Figure 3

Neoplastic lesions developed in rat reflux models. (a) Dysplasia. (b) Mucinous adenocarcinoma.

Various rat reflux models of Barrett's esophagus leading to adenocarcinoma. F, forestomach; G, glandular stomach; T, treitz ligament. (a) Esophago‐jejunostomy after total gastrectomy.86, 87 (b) Esophago‐jejunostomy without gastrectomy.87, 88 (c) The esophagogastric junction was side‐to‐side anastomosed to a loop of jejunum.93 Neoplastic lesions developed in rat reflux models. (a) Dysplasia. (b) Mucinous adenocarcinoma.

DEVELOPMENT OF BARRETT'S EPITHELIUM

Many hypotheses have been reported regarding the cells from which Barrett's mucosa originates. These include (i) the columnar epithelium being directly produced from the esophageal squamous epithelium87, 89, 90 (Fig. 4a); (ii) the gastric mucosa77, 91 (Fig. 4b); (iii) the esophageal gland duct92 (Fig. 4c); (iv) the esophagogastric junction mucosa93 (Fig. 4d); (v) the fetal remnant94 (Fig. 4e,f); (vi) bone marrow cells95 (Fig. 4g); and (vii) wound repair.96 Most of these hypotheses have been developed based on results from rat‐ or mouse‐based models. The genetic changes have typically been evaluated in mice, because of their well‐understood genome. However, mice and rats differ anatomically from humans, as they lack esophageal glands, which makes it impossible to determine whether Barrett's mucosa develops from these glands. Furthermore, rats lack a gall bladder, and the surgically induced model causes continuous bile reflux based on the absence of a gallbladder. Pigs have also been used to study whether the esophageal glands are involved in the occurrence of EAC from Barrett's epithelium. It is impossible to definitively identify the correct theory and research in this field is expected to continue. In the following sections, we will introduce the process based on the findings from our rat gastroduodenal reflux models.77, 87, 88 There are at least two ways for Barrett's epithelium to develop.77
Figure 4

Various candidate lesions about development of Barrett's epithelium. (a,c–e,g) HE stainings. (b) CDX2. (f) CK7 Visualization of immunochemical staining was performed using 3,3′‐diaminobenzadine (DAB). (a) Inflamed esophageal squamous epithelium. (b) Gastric mucosa (cardiac‐type mucosa) focally positive for CDX2 expression has the potential for intestinal differentiation. (Brown is the color of positive cells). (c) Esophageal gland duct. (d) Esophagogastric junction mucosa. (e,f) Twenty‐two‐week‐old human fetal esophagi. The epithelium has cilia, and it is positive for CK7. (f) Bone marrow.

Various candidate lesions about development of Barrett's epithelium. (a,c–e,g) HE stainings. (b) CDX2. (f) CK7 Visualization of immunochemical staining was performed using 3,3′‐diaminobenzadine (DAB). (a) Inflamed esophageal squamous epithelium. (b) Gastric mucosa (cardiac‐type mucosa) focally positive for CDX2 expression has the potential for intestinal differentiation. (Brown is the color of positive cells). (c) Esophageal gland duct. (d) Esophagogastric junction mucosa. (e,f) Twenty‐two‐week‐old human fetal esophagi. The epithelium has cilia, and it is positive for CK7. (f) Bone marrow.

Development from the basal layer of the esophageal squamous epithelium

In the rat reflux models, columnar epithelium was observed in the basal layer of the squamous epithelium, which involved regenerative changes caused by inflammation at locations distant from the anastomosis (Fig. 5). This process cannot be attributed to transdifferentiation (i.e., completely differentiated squamous epithelium differentiating into columnar epithelium) and must be attributed to transcommitment, in which stem cells located in the basal layer of the stratified squamous epithelium change their direction of differentiation from squamous to columnar epithelium. In a review on reflux esophagitis by Souza, an alternative concept to the conventional theory of ‘reflux esophagitis is an acid burn’ is proposed. According to this concept, ‘the reflux of acid and bile salts does not destroy epithelial cells directly, but rather induces them to secrete pro‐inflammatory cytokines’. Columnar epithelium that exists in the squamous epithelial basal layer is thought to develop as a result of cytokine sizzle.97 One recent report has described a non‐neoplastic cell line established from the esophageal stratified squamous epithelium of a patient with GERD who experienced bile acid reflux for approximately 5 min daily over a 30‐week period. That cell line exhibited expression of TAp63, CDX2 and SOX9, similar to cell lines established from Barrett's epithelium, as well as similar morphological changes.98 They suggested that the non‐neoplastic cell line, which was derived from a biopsy specimen of a patient with GERD, may be derived from preterminal parent cells that retain the proliferative capacity and may not represent true ‘fully terminally differentiated’ epithelial cells. Considering their precursor‐like properties, this behavior is more synonymous with reprogramming or transcommitment rather than transdifferentiation.98 They claimed that these biphenotypic progenitors may be the precursors for the Barrett's columnar epithelium.98
Figure 5

Histological image of a site distant from the anastomotic region in a rat model that underwent esophago‐jejunostomy. Several columnar epithelia have developed within the squamous epithelium, as shown on the right side of the figure, while complete Barrett's epithelium (arrow) can be seen on the left side of the figure.

Histological image of a site distant from the anastomotic region in a rat model that underwent esophago‐jejunostomy. Several columnar epithelia have developed within the squamous epithelium, as shown on the right side of the figure, while complete Barrett's epithelium (arrow) can be seen on the left side of the figure.

Development from the cardiac‐type mucosa

This section addresses the development of cardiac‐type mucosa, which is commonly associated with SSBE in Japan. Results from our animal models, which mimic human gastroduodenal reflux through the esophagogastric junction (Fig. 6), have suggested that cardiac‐type mucosa forms Barrett's mucosa by spreading to the oral side, which replaces the place where esophageal stratified squamous epithelium is missing because of erosion or ulceration77 (Fig. 7). This is so‐called ‘creeping theory’, which involves stem cells around the missing epithelium gradually spreading to cover the defect without overt proliferative activity. Thus, if reflux esophagitis is not treated (e.g., by using a proton pump inhibitor (PPI)), there is a persistent cause of the defect in the esophageal mucosa. Furthermore, with sustained reflux, the cardiac glands spread to the oral side faster than the oral‐side squamous epithelium can repair the defect. The squamous epithelium is also more vulnerable to gastric acid or bile than the gastric columnar epithelium, which makes it impossible to restore the missing epithelium if there is sustained reflux. In contrast, endoscopic images from cases treated using a PPI had frequently revealed signs that the defect sites from before PPI therapy were repaired by stratified squamous epithelium. Therefore, it appears that replacement of the missing mucosal epithelium by stratified squamous epithelium or columnar epithelium depends on the local environment, which is related to the presence or absence of sustained reflux.
Figure 6

Surgical procedure of the rat model which mimics human gastroduodenal reflux: F, forestomach; G, glandular stomach; T, treitz ligament. Surgery proceeds from left to right. The final phase is shown on the extreme right. Firstly, we removed the forestomach which does not exist in the human stomach. Then, the esophagus was connected with the glandular stomach. The gastrointestinal tract is sectioned where the red double line is drawn in the second figure from the right and then anastomosed. In the final phase, the reflux of gastric fluid that contains duodenal fluid occurs from the glandular stomach to the esophagus (yellow arrow).

Figure 7

Cardiac‐type mucosa around the esophagoglandular‐stomach anastomosis developed in the rat reflux model. The right side of the figure is an oral side. Expansion of intrinsic gastric cardiac glands occurs to cover the defect of squamous epithelium during wound repair (arrow).

Surgical procedure of the rat model which mimics human gastroduodenal reflux: F, forestomach; G, glandular stomach; T, treitz ligament. Surgery proceeds from left to right. The final phase is shown on the extreme right. Firstly, we removed the forestomach which does not exist in the human stomach. Then, the esophagus was connected with the glandular stomach. The gastrointestinal tract is sectioned where the red double line is drawn in the second figure from the right and then anastomosed. In the final phase, the reflux of gastric fluid that contains duodenal fluid occurs from the glandular stomach to the esophagus (yellow arrow). Cardiac‐type mucosa around the esophagoglandular‐stomach anastomosis developed in the rat reflux model. The right side of the figure is an oral side. Expansion of intrinsic gastric cardiac glands occurs to cover the defect of squamous epithelium during wound repair (arrow).

Summary of the development of Barrett's mucosa

Based on the results of studies that used rat reflux models, at least two pathways are involved in the development of Barrett's esophagus. We believe SSBE development can be explained by spreading of a cardiac‐type mucosa to the oral side due to wound repair, while LSBE development can be explained by the presence of progenitor cells or stem cells in the basal layer of the esophageal stratified squamous epithelium transcommitment, as a result of cytokine sizzle. These two pathways may be simultaneously involved in human cases. A developmental process that involves the esophageal glands may also exist that cannot be verified using rats, which have no esophageal glands.

BARRETT'S CARCINOGENSIS

Effects of a high‐animal‐fat diet

Although Humans who have developed Barrett's esophagus reportedly had greater bile acid reflux in the esophagus,99 it remains unclear which bile acids are involved in carcinogenesis from Barrett's esophagus. Nehra et al.99 have reported that significant amounts of taurine‐conjugated bile acids were detected in the esophagi of patients who had developed Barrett's esophagus. In the US, the increase in the incidence of Barrett's esophagus is reportedly linked to the consumption of a high‐fat diet,8 and our rat model has shown that a high‐fat diet consisting mainly of tallow increases the proportion of taurine‐conjugated bile acids.100 The pH in the stomach and the acid dissociation constant of each bile acid need to be considered. The pKa value of taurine conjugates is strikingly lower at approximately 1.8 to 1.9 and taurine conjugates do not form deposits,101 even in cases with bile acid reflux into the stomach.

Activation of NF‐κB

In vitro experiments also indicated that taurine‐conjugated bile acids activate Src, EGFR and ERK, thereby causing colorectal cancer cells to proliferate.102 Activation of nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB), which is reportedly overexpressed after exposure to bile acids, has also been implicated in carcinogenesis from Barrett's esophagus.103 It has also been reported that acid and bile acids caused activation of NF‐κB.104, 105 Bile acids are known to increase CDX1 and CDX2 expression and promote differentiation into intestinal epithelium.89, 106, 107, 108, 109, 110 CDX2 is targeted by the NF‐κB pathway,111, 112 and two putative NF‐κB binding sites have been identified in the CDX2 promoter.113 Therefore, digestive juice reflux induces the production of cytokines that are involved in Barrett's carcinogenesis. This carcinogenic process is likely initiated by a factor that is produced in the patient's body, and we will cover some potential factors below.

Production and stabilization of N‐nitroso‐bile acids

Nnitroso‐compounds have been implicated in the occurrence of gastric cancer,114 and endogenous N‐nitrosobile acids are one kind of nitroso compounds. Although bile acid itself is not mutagenic, N‐nitrosobile acids are mutagenic and are produced if nitrite or nitrate and bile acid are present in acidic conditions. Based on our reflux models, we found that administration of L‐thioproline (which plays a role in capturing nitrite) suppressed the occurrence of esophageal or gastric cancer, which indirectly shows that N‐nitrosobile acids are involved in the occurrence of esophageal and gastric cancers.115, 116 DNA adducts originating from N‐nitrosobile acids have also been detected in the glandular stomach from our gastric cancer model.117, 118 Furthermore, N‐nitrosobile acids reportedly stabilize under acidic conditions.119 These findings suggest that N‐nitrosobile acids appear to be involved in the occurrence of EAC from Barrett's esophagus in patients with healthy acid‐secreting stomachs.

Why have the prevalence of EAC and esophagogastric junction cancer increased in tandem?

A report has indicated that the American prevalence of EAC and esophagogastric junction cancer have increased in tandem.8 The increasing American prevalence of EAC and esophagogastric junction cancer seem to be related to GERD. Even healthy individuals experience regurgitation of duodenal fluid into the stomach after eating,120 and the amount regurgitated increases in patients with GERD reportedly. Thus, lying down after eating can result in the duodenal fluid, which contains bile acids, remaining in the stomach (e.g., during sleep).121 Suzuki et al.122 have reported that the cardia has the highest concentration of nitrates originating from food, which maximizes the luminal generation of N‐nitroso‐compounds from dietary nitrate at the most proximal cardiac region of the acidic stomach. Because the accumulated reflux fluid would contain endogenous N‐nitrosobile acids from the stomach, chronic inflammation and carcinogenesis could then occur in the esophagogastric junction or esophagus. Fig. 8 shows this process from the left oblique position, based on a roughly sagittal cross‐section that is parallel to the major axis of the esophagogastric junction from the esophagus. The esophagus descends from the oral side to the caudal side along the left side of the aorta, but then proceeds to the right ventral side slightly cranial to the diaphragmatic hiatus, which allows it to pass ventral to the aorta and enter the abdominal cavity near the body's midline, where it transitions into the stomach. If the individual lies down immediately after eating, the food remains in the stomach and collects in the fornix on the dorsal side. When transient lower esophageal sphincter relaxations occur in this state, the esophagogastric junction and lower esophagus would be exposed to these liquids. It is also theoretically possible that the liquids include N‐nitrosobile acids, which may play a role in the initiation of carcinogenesis. Thus, the prevalence of EAC and esophagogastric junction cancer has increased in tandem.
Figure 8

The mechanism of EAC and esophagogastric junction cancer development: A, aorta; L, liver; P, pancreas; S, stomach; f, food remnants. The figure is the schema from the left oblique position of the patient with GERD. The right side of the figure is a head side, and the left side is caudal. If the individual lies down immediately after eating, the food remains in the stomach and collects in the fornix on the dorsal side. The ventral side of the food remnants also includes a component that contains liquid or sludge‐like digestive juice, which would also include duodenal fluid including bile acids. The accumulated reflux fluid (arrow) would contain endogenous N‐nitroso‐bile acids, and carcinogenesis could then occur in the esophagogastric junction or esophagus.

The mechanism of EAC and esophagogastric junction cancer development: A, aorta; L, liver; P, pancreas; S, stomach; f, food remnants. The figure is the schema from the left oblique position of the patient with GERD. The right side of the figure is a head side, and the left side is caudal. If the individual lies down immediately after eating, the food remains in the stomach and collects in the fornix on the dorsal side. The ventral side of the food remnants also includes a component that contains liquid or sludge‐like digestive juice, which would also include duodenal fluid including bile acids. The accumulated reflux fluid (arrow) would contain endogenous N‐nitrosobile acids, and carcinogenesis could then occur in the esophagogastric junction or esophagus.

CONCLUSION

Barrett's epithelium involves metaplasia of the squamous epithelium into columnar epithelium, which could be described as an adaptation in a microenvironment.123, 124, 125 The microenvironment is decided by mainly bile acids and gastric acid in gastric juice flow backward into the esophagus. Bile acids are known to promote differentiation into intestinal epithelium by increasing the CDX1 and CDX2 expression. Although Barrett's epithelium with intestinal metaplasia involves a higher risk of carcinogenesis than if intestinal metaplasia was absent, cardiac‐type mucosa which has the potential to involve intestinal phenotypes can be a risk of EAC. Digestive juice reflux including the high concentration of bile acids induces the production of cytokines, such as NF‐κB, has been implicated in carcinogenesis from Barrett's esophagus. This carcinogenic process is likely initiated by the production of N‐nitrosobile acids, which is mutagenic and promoted by sustained chronic inflammation.

DISCLOSURE STATEMENT

None declared.

AUTHOR CONTRIBUTIONS

KM wrote the paper. SK, RK, TN, TH and HS participated in discussions during the writing of the paper and offered valuable advice.
  118 in total

1.  Ducts of esophageal glands proper and paneth cells in Barrett's esophagus: frequency in biopsy specimens.

Authors:  K Takubo; J M Nixon; J R Jass
Journal:  Pathology       Date:  1995-10       Impact factor: 5.306

2.  Barrett's metaplasia develops from cellular reprograming of esophageal squamous epithelium due to gastroesophageal reflux.

Authors:  Carlos D Minacapelli; Manisha Bajpai; Xin Geng; Christina L Cheng; Abhishek A Chouthai; Rhonda Souza; Stuart J Spechler; Kiron M Das
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-03-23       Impact factor: 4.052

3.  Surveillance of patients with long-segment Barrett's esophagus: A multicenter prospective cohort study in Japan.

Authors:  Nobuyuki Matsuhashi; Eiji Sakai; Ken Ohata; Norihisa Ishimura; Junko Fujisaki; Tomoki Shimizu; Katsunori Iijima; Tomoyuki Koike; Takao Endo; Takefumi Kikuchi; Tatsuya Inayoshi; Yuji Amano; Takahisa Furuta; Ken Haruma; Yoshikazu Kinoshita
Journal:  J Gastroenterol Hepatol       Date:  2017-02       Impact factor: 4.029

4.  Islands of squamous epithelium and their surrounding mucosa in columnar-lined esophagus: a pathognomonic feature of Barrett's esophagus?

Authors:  Kaiyo Takubo; Michael Vieth; Gopi Aryal; Naoko Honma; Motoji Sawabe; Tomio Arai; Makoto Kammori; Ken-Ichi Mafune; Katsuhiko Iwakiri
Journal:  Hum Pathol       Date:  2005-03       Impact factor: 3.466

5.  Thioproline prevents carcinogenesis in the remnant stomach induced by duodenal reflux.

Authors:  Masashi Suo; Ken-Ichi Mukaisho; Akihiko Shimomura; Hiroyuki Sugihara; Takanori Hattori
Journal:  Cancer Lett       Date:  2005-07-26       Impact factor: 8.679

Review 6.  Reflux esophagitis and its role in the pathogenesis of Barrett's metaplasia.

Authors:  Rhonda Frances Souza
Journal:  J Gastroenterol       Date:  2017-04-27       Impact factor: 7.527

7.  In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor-κB and activator protein-1.

Authors:  Xiaofang Huo; Xi Zhang; Chunhua Yu; Qiuyang Zhang; Edaire Cheng; David H Wang; Thai H Pham; Stuart J Spechler; Rhonda F Souza
Journal:  Gut       Date:  2013-09-18       Impact factor: 23.059

Review 8.  The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis.

Authors:  Fouad Yousef; Chris Cardwell; Marie M Cantwell; Karen Galway; Brian T Johnston; Liam Murray
Journal:  Am J Epidemiol       Date:  2008-06-12       Impact factor: 4.897

9.  Japanese Classification of Esophageal Cancer, 11th Edition: part I.

Authors: 
Journal:  Esophagus       Date:  2016-11-10       Impact factor: 4.230

10.  Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway.

Authors:  Jun-Hui Yu; Jian-Bao Zheng; Jie Qi; Kui Yang; Yun-Hua Wu; Kai Wang; Chun-Bao Wang; Xue-Jun Sun
Journal:  Int J Oncol       Date:  2019-01-22       Impact factor: 5.650

View more
  8 in total

1.  Gualou Xiebai Decoction ameliorates increased Caco-2 monolayer permeability induced by bile acids via tight junction regulation, oxidative stress suppression and apoptosis reduction.

Authors:  Jiyuan Su; Zhiqing He; Yunhua Yu; Mingfang Lu; Zonggui Wu; Dongmei Zhang
Journal:  J Bioenerg Biomembr       Date:  2021-10-31       Impact factor: 2.945

2.  Mechanisms of Chinese Medicine in Gastroesophageal Reflux Disease Treatment: Data Mining and Systematic Pharmacology Study.

Authors:  Hao-Yu Chen; Qi Li; Ping-Ping Zhou; Tian-Xiao Yang; Shao-Wei Liu; Teng-Fei Zhang; Zhen Cui; Jing-Jing Lyu; Yan-Gang Wang
Journal:  Chin J Integr Med       Date:  2022-08-23       Impact factor: 2.626

3.  Laparoscopic conversion of omega loop gastric bypass to Roux-en-Y gastric bypass for Barrett's esophagus: case report.

Authors:  U G Lange; Y Moulla; M Mehdorn; J Tuennemann; A Zabel-Langhennig; A Ouaid; A Dietrich
Journal:  BMC Surg       Date:  2022-07-14       Impact factor: 2.030

4.  Potential roles of gastroesophageal reflux in patients with superficial esophageal squamous cell carcinoma without major causative risk factors.

Authors:  Takehide Fukuchi; Kingo Hirasawa; Chiko Sato; Makomo Makazu; Hiroaki Kaneko; Ryosuke Kobayashi; Masafumi Nishio; Ryosuke Ikeda; Atsushi Sawada; Yuichiro Ozeki; Makoto Sugimori; Yoshiaki Inayama; Yoko Tateishi; Shin Maeda
Journal:  J Gastroenterol       Date:  2021-08-23       Impact factor: 7.527

5.  Trefoil factor 1 inhibits the development of esophageal adenocarcinoma from Barrett's epithelium.

Authors:  Keiji Hasebe; Kimitoshi Yamazaki; Junpei Yamaguchi; Toshio Kokuryo; Yukihiro Yokoyama; Kazushi Miyata; Masahide Fukaya; Masato Nagino; Tomoki Ebata
Journal:  Lab Invest       Date:  2022-03-12       Impact factor: 5.502

6.  Development of Pancreatic Acinar Cell Metaplasia During Gastric Repair in a Rat Duodenal Contents Reflux Model.

Authors:  Yasuhiro Wada; Ken-Ichi Mukaisho; Shunpei Kanai; Takahisa Nakayama; Masahide Fukuda; Kazuhiro Mizukami; Tadayoshi Okimoto; Masaaki Kodama; Hiroyuki Sugihara; Kazunari Murakami; Ryoji Kushima
Journal:  Dig Dis Sci       Date:  2020-05-21       Impact factor: 3.199

7.  Influence of Oral Intaking Habit on Tongue Coating Microbiota in Patients with Esophageal Precancerous Lesions.

Authors:  Pan Xiao; Zhaolai Hua; Xiaoyu Kang; Bin Lu; Meifeng Li; Juan Wu; Wei Dong; Junfeng Zhang; Chun Cheng
Journal:  J Cancer       Date:  2022-01-16       Impact factor: 4.207

8.  IL-33 Participates in the Development of Esophageal Adenocarcinoma.

Authors:  Jia Liu; Lei Liu; Yang Su; Yi Wang; Yuchun Zhu; Xiaobin Sun; Yuanbiao Guo; Jing Shan
Journal:  Pathol Oncol Res       Date:  2022-08-30       Impact factor: 2.874

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.